A Conversation on Women's Leadership and Career in Medicine: Jennifer Frontera, MD
February 3rd 2024The professor of neurology at NYU Grossman School of Medicine talked about the importance of aligning leadership roles with personal passions for women in the field of neurology pursuing their careers in medicine. [WATCH TIME: 5 minutes]
Case Study Reports Positive Impact of Antiviral Therapy Tenofovir in MS, Warranting Further Research
February 3rd 2024In a case report, an HIV-positive patient with active multiple sclerosis showed reduced disease activity with tenofovir-containing antiretrovirals, suggesting potential MS treatment benefits.
The Next Wave of Stroke Care Beyond the Acute Phase: Matthew Schrag, MD, PhD
February 2nd 2024The associate professor of neurology at Vanderbilt University Medical Center discussed exploring promising opportunities in other phases outside of the acute phase of ischemic stroke. [WATCH TIME: 3 minutes]
Transformation of Rett Syndrome Research With the Emergence of Adult Data: Walter E. Kaufmann, MD
February 2nd 2024The adjunct professor of human genetics at Emory University School of Medicine discussed previous research on Rett syndrome that initially provided crucial insight on the neuromuscular condition in adult populations. [WATCH TIME: 2 minutes]
Advocating and Advancing Research in NMOSD From a Patient Perspective: Sumaira Ahmed
February 1st 2024The founder and executive director of the Sumaira Foundation shared her patient journey living with NMOSD and the progress that has been made in the field over the past decade. [WATCH TIME: 4 minutes]
Key Components Identified for Improving Efficacy of Cognitive Behavioral Therapy in Chronic Insomnia
February 1st 2024A recent review revealed critical components, including cognitive restructuring and third-wave strategies, that enhance the effectiveness of cognitive behavioral therapy for insomnia.
Making Improvements to Geographic Spacing, Access to Neurologists and MS Care
February 1st 2024Marisa McGinley, DO, a staff neurologist at Cleveland Clinic’s Mellen Center for MS Treatment and Research, provided forward thoughts on the healthcare reach of neurologists and care access for patients with multiple sclerosis.
Shared Decision-Making Intervention MS-SUPPORT Provides Several Benefits to Patients With MS
January 31st 2024An online shared decision-making tool showed feasibility in most patients with multiple sclerosis, with reported improvements in understanding treatment options and adherence to treatment.
Lessons in Migraine Medicine and Changes to the Treatment Toolbox: Stephen Samples, MD
January 31st 2024The chair of Allegheny Health Network’s department of neurology provided insight on his clinical experiences with migraine medicine and how the field needs to adapt to the ongoing changes to treatment options. [WATCH TIME: 4 minutes]
The Global Crisis of Misdiagnosis and Challenges in Care for Rare Diseases: Sumaira Ahmed
January 30th 2024The founder and executive director of the Sumaira Foundation discussed the increasing amount of misdiagnosis in rare diseases such as NMOSD and how it impacts these patients in terms of care and support. [WATCH TIME: 2 minutes]
Positive Phase 2 Data Announced for MOMENTUM Study of Duchenne Agent SRP-5051
January 30th 2024Over a 28-week treatment period, the investigational agent demonstrated significantly greater increase in dystrophin expression and exon skipping than previously approved eteplirsen, Sarepta’s first therapy for Duchenne muscular dystrophy.
Insights on GBA1-Targeting Agent GT-02287 for Parkinson Disease: Joanne Taylor, PhD
January 29th 2024The senior vice president of research at Gain Therapeutics talked about preclinical findings from a study assessing GT-02287, an agent in development for the treatment of GBA1 Parkinson disease, and future plans for clinical trials. [WATCH TIME: 7 minutes]
Patient Perspective on the Health Canada Approval of Inebilizumab for NMOSD: Sumaira Ahmed
January 29th 2024The founder and executive director of the Sumaira Foundation shared her patient perspective of Health Canada’s approval of inebilizumab in terms of its implications for patients and how it paves the way for future treatments in NMOSD. [WATCH TIME: 3 minutes]